Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
Status:
Active, not recruiting
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to compare how 2 different drugs, decitabine and
azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS.
The safety of each study drug given on these schedules will also be studied.
This is an investigational study. Decitabine and azacitidine are both FDA approved and
commercially available for use in patients with MDS. Giving these drugs on a different
schedule than is standard is considered investigational.
The study doctor can tell you how the study drugs are designed to work.
Up to 240 participants will be enrolled in this multicenter study. Up to 157 will take part
at MD Anderson.